EMEA-001501-PIP06-20 - paediatric investigation plan

dupilumab

Key facts

• Invented name:
  Dupixent
• Active Substance:
  dupilumab
• Therapeutic area:
  Dermatology
• Decision number:
  P/0394/2020
• PIP number:
  EMEA-001501-PIP06-20
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of prurigo nodularis
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  23/10/2020

Decision

P/0394/2020 : EMA decision of 23 October 2020 on the granting of a product specific waiver for dupilumab (Dupixent), (EMEA-001501-PIP06-20)

AdoptedReference Number: EMA/534986/2020